224 related articles for article (PubMed ID: 31820498)
41. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
42. Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center.
Onsun N; Güneş B; Yabacı A
Dermatol Ther; 2021 Jan; 34(1):e14623. PubMed ID: 33274541
[TBL] [Abstract][Full Text] [Related]
43. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
[TBL] [Abstract][Full Text] [Related]
44. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.
Armstrong AW; Feldman SR; Korman NJ; Meng X; Guana A; Nyirady J; Herrera V; Zhao Y
J Dermatolog Treat; 2017 May; 28(3):200-205. PubMed ID: 27541729
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3.
Kemény L; Berggren L; Dossenbach M; Dutronc Y; Paul C
J Dermatolog Treat; 2019 Feb; 30(1):19-26. PubMed ID: 29726739
[TBL] [Abstract][Full Text] [Related]
46. Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity.
García-Rodríguez S; Arias-Santiago S; Blasco-Morente G; Orgaz-Molina J; Rosal-Vela A; Navarro P; Magro-Checa C; Martínez-López A; Ruiz JC; Raya E; Naranjo-Sintes R; Sancho J; Zubiaur M
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):312-322. PubMed ID: 27535005
[TBL] [Abstract][Full Text] [Related]
47. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
48. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of biologic therapies in psoriasis vulgaris.
Mala R; Fida M; Jorgaqi E; Vasili E
Dermatol Ther; 2019 Jul; 32(4):e12936. PubMed ID: 30983095
[TBL] [Abstract][Full Text] [Related]
50. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ
Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371
[TBL] [Abstract][Full Text] [Related]
51. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.
Xie F; Wang R; Zhao ZG; Meng XF; Lin BW; Yang J; Wang WJ; Ding XY; Yang Y; Zhao H; Li CX; Li HJ; Zhou Y
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):943-947. PubMed ID: 29270758
[TBL] [Abstract][Full Text] [Related]
53. Association of the Psoriatic Microenvironment With Treatment Response.
Wang G; Miao Y; Kim N; Sweren E; Kang S; Hu Z; Garza LA
JAMA Dermatol; 2020 Oct; 156(10):1057-1065. PubMed ID: 32876657
[TBL] [Abstract][Full Text] [Related]
54. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
Warren RB; Halliday A; Graham CN; Gilloteau I; Miles L; McBride D
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965
[TBL] [Abstract][Full Text] [Related]
55. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
[TBL] [Abstract][Full Text] [Related]
56. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
Zweegers J; Roosenboom B; van de Kerkhof PC; van den Reek JM; Otero ME; Atalay S; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Bijen M; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2017 Mar; 176(3):786-793. PubMed ID: 27454758
[TBL] [Abstract][Full Text] [Related]
57. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
[TBL] [Abstract][Full Text] [Related]
58. Correlation of microRNA-125a/b with acute respiratory distress syndrome risk and prognosis in sepsis patients.
Li S; Zhao D; Cui J; Wang L; Ma X; Li Y
J Clin Lab Anal; 2020 Mar; 34(3):e23098. PubMed ID: 31967348
[TBL] [Abstract][Full Text] [Related]
59. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.
Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B
Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117
[TBL] [Abstract][Full Text] [Related]
60. The correlation of long non-coding RNA NEAT1 and its targets microRNA (miR)-21, miR-124, and miR-125a with disease risk, severity, and inflammation of allergic rhinitis.
Wang R; Xue S; Liu Y; Peng M; Guo B
Medicine (Baltimore); 2021 Jan; 100(4):e22946. PubMed ID: 33530155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
